Coherus Oncology (FRA:8C5) Total Current Assets: €178.22 Mil (As of Mar. 2026)

What is Coherus Oncology Total Current Assets?

Coherus Oncology FRA:8C5 +6.53% 44 Total Current Assets is €178.22 Mil as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 44/100 and a GF Value™ of €0.62 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Coherus Oncology's total current assets for the quarter that ended in Mar. 2026 was €178.22 Mil.

Coherus Oncology (FRA:8C5) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Coherus Oncology's Liquidation Value for the quarter that ended in Mar. 2026 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	144.497	-	162.1	+	0.75 * 19.085	+	0.5 * 4.174
=	-1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology Total Current Assets Related Terms

Coherus Oncology Total Current Assets Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's Total Current Assets can be seen below:

Coherus Oncology Total Current Assets Chart

Coherus Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Current Assets

Get a 7-Day Free Trial

533.06

359.89

436.15

326.21

176.53

Coherus Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Current Assets	Get a 7-Day Free Trial															286.91	329.64	392.73	176.53	178.22

44GF Score

Coherus Oncology Inc FRA:8C5

Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coherus Oncology Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Coherus Oncology's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	146.995	+	15.729	+	2.709	+	11.094
	=	176.53

Coherus Oncology's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	144.497	+	19.471	+	4.174	+	10.078
	=	178.22

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →

What does a Total Current Assets of €178.22 Mil mean?

Coherus Oncology (FRA:8C5) has a Total Current Assets of €178.22 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Coherus Oncology and its competitors.

Is Coherus Oncology's Total Current Assets too high?

Coherus Oncology's current Total Current Assets is €178.22 Mil. Overall, Coherus Oncology has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Coherus Oncology's Total Current Assets compare to TARA and KPTI?

Coherus Oncology's Total Current Assets of €178.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Current Assets for a Biotechnology company?

A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Current Assets mean?

A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Coherus Oncology and its competitors. Coherus Oncology's current Total Current Assets is €178.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coherus Oncology stock overvalued right now?

Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.62, compared to a current price of €1.34 — trading 115.8% above its estimated fair value. The current Total Current Assets is €178.22 Mil. Coherus Oncology's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Current Assets calculated?

Total Current Assets is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Total Current Assets is €178.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.34 is trading 115.8% above its estimated GF Value™ of €0.62. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

Total Current Assets: €178.22 Mil
GF Value™: €0.62 vs. price of €1.34 (115.8% above fair value)
GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies TARA KPTI CNTN RNA QTTB AVXL SLGL CAMP CDXS KROS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CHRS:USA

Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website https://www.coherus.com

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

44GF Score

Get the complete analysis for FRA:8C5

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.34

Price

€0.62

GF Value

View FRA:8C5 Analysis

See Total Current Assets data for all stocks →